-
Nov 4, 2024 | 
urologytimes.com | Fred Saad
OpinionVideoNovember 4, 2024Author(s):Panelists discuss how the increased use of androgen receptor–targeted therapy in clinical practice may impact the effectiveness of PARP inhibitor combinations like talazoparib in the TALAPRO-2 study, while also addressing safety concerns, potential differences in trial populations, and the need for future studies to optimize treatment approaches for various metastatic prostate cancer patient subgroups.
-
Nov 4, 2024 | 
urologytimes.com | Fred Saad
OpinionVideoNovember 4, 2024Author(s): Olaparib significantly improved radiographic progression-free survival and overall survival in metastatic prostate cancer with HRR gene alterations. Safety profiles of PARP inhibitors were consistent with known effects, with manageable adverse events observed. The PROfound trial underscores the importance of genetic testing to guide personalized treatment decisions in prostate cancer.
-
Oct 28, 2024 | 
urologytimes.com | Fred Saad
OpinionVideoOctober 28, 2024Author(s):Panelists discuss how PARP inhibitor monotherapy trials like TALAPRO-1 (talazoparib) and TRITON-3 (rucaparib) have demonstrated efficacy and safety in treating metastatic prostate cancer patients with homologous recombination repair gene alterations, providing important insights into targeted therapy options for this specific patient population.
-
Oct 25, 2024 | 
onclive.com | Fred Saad
CommentaryVideoOctober 25, 2024Fact checked by:,Fred Saad, CQ, MD, FRCS, FCAHS, discusses the safety findings from the phase 3 ARANOTE trial investigating darolutamide plus ADT in patients with mHSPC.
-
Oct 21, 2024 | 
urologytimes.com | Fred Saad
OpinionVideoOctober 21, 2024Author(s): The PEACE III study explores combining radium-223 with androgen receptor-targeted therapies to improve PSA control in prostate cancer treatment. Radium-223's poor clinical uptake is due to its inability to control PSA alone, necessitating combination with androgen receptor inhibitors. Combining radium-223 with enzalutamide leverages two distinct mechanisms of action, potentially enhancing treatment efficacy.
-
Oct 21, 2024 | 
urologytimes.com | Fred Saad
OpinionVideoOctober 21, 2024Author(s): The ARANOTE trial enables personalized cancer treatment, allowing oncologists to tailor therapy based on individual patient needs and clinical situations. Flexibility in the trial design accommodates varying patient profiles, optimizing treatment outcomes and enhancing therapeutic decision-making. The trial's approach is particularly beneficial in managing complex cases where standard protocols may not be suitable, improving patient care and satisfaction.
-
Oct 14, 2024 | 
urologytimes.com | Fred Saad
OpinionVideoOctober 14, 2024Author(s):The panelist discusses how the ARANOTE trial demonstrated significant benefits of adding darolutamide to androgen deprivation therapy for patients with metastatic hormone-sensitive prostate cancer, showing improvements in radiographic progression-free survival and other key outcomes.
-
Oct 14, 2024 | 
urologytimes.com | Fred Saad
OpinionVideoOctober 14, 2024Author(s):Fred Saad, CQ, MD, FRCS, FCAHS, discusses how darolutamide offers potential advantages over other androgen receptor–targeted therapies for metastatic prostate cancer, including its unique molecular structure, favorable safety profile, and efficacy in specific clinical scenarios. Video Content above is prompted by the following:What are some of the benefits of darolutamide over other androgen receptor–targeted therapies?
-
Oct 7, 2024 | 
urologytimes.com | Fred Saad
OpinionVideoOctober 7, 2024Author(s):The panelist discusses how patient characteristics, disease factors, and individual health status guide the decision to include or avoid chemotherapy in combination treatments for metastatic prostate cancer, weighing potential benefits against risks and quality of life considerations. Video Content above is prompted by the following:For which patients would you choose or avoid a combination that includes chemotherapy?
-
Oct 7, 2024 | 
urologytimes.com | Fred Saad
OpinionVideoOctober 7, 2024Author(s): Chemotherapy, particularly docetaxel, significantly influences the adverse event profile, with common side effects including neutropenia, fatigue, and diarrhea. The ARASENS trial findings align with previous studies, confirming the consistency of observed adverse effects with clinical practice. Effective monitoring and management of adverse events are crucial for optimizing patient outcomes and maintaining quality of life during chemotherapy.
